147 related articles for article (PubMed ID: 37076364)
1. Evaluating the Necessity for Routine Sentinel Lymph Node Biopsy in Postmenopausal Patients Being Treated for Clinically Node Negative Breast Cancer the Era of RxPONDER.
Davey MG; Kerin EP; McLaughlin RP; Barry MK; Malone CM; Elwahab SA; Lowery AJ; Kerin MJ
Clin Breast Cancer; 2023 Jul; 23(5):500-507. PubMed ID: 37076364
[TBL] [Abstract][Full Text] [Related]
2. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR
Pilewskie M; Sevilimedu V; Eroglu I; Le T; Wang R; Morrow M; Braunstein LZ
Ann Surg Oncol; 2022 Oct; 29(10):6267-6273. PubMed ID: 35849294
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?
Lee E; Tweed C; Mylander C; Martino L; Rosman M; Huerta N; Waite K; Tafra L; Jackson RS
Clin Breast Cancer; 2021 Dec; 21(6):e731-e737. PubMed ID: 34006481
[TBL] [Abstract][Full Text] [Related]
4. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
Kantor O; Weiss A; Burstein HJ; Mittendorf EA; King TA
Ann Surg Oncol; 2022 Nov; 29(12):7674-7682. PubMed ID: 35763229
[TBL] [Abstract][Full Text] [Related]
5. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
6. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles in clinically T1-2N0 ER+HER2- breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed.
van Roozendaal LM; Vane MLG; Colier E; Strobbe LJA; de Boer M; Sonke G; Van Maaren MC; Smidt ML
Breast Cancer Res Treat; 2024 Jan; 203(1):103-110. PubMed ID: 37794289
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
9. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?
Farley C; Bassett R; Meric-Bernstam F; Bedrosian I; Caudle A; DeSnyder S; Hunt K; Kuerer H; Singh P; Sun S; Tamirisa N; Teshome M; Hwang RF
Ann Surg Oncol; 2023 Dec; 30(13):8327-8334. PubMed ID: 37670121
[TBL] [Abstract][Full Text] [Related]
10. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Garcia-Tejedor A; Falo C; Fernandez-Gonzalez S; Laplana M; Gil-Gil M; Soler-Monso T; Martinez-Perez E; Calvo I; Calpelo H; Bajen MT; Benitez A; Ortega R; Petit A; Guma A; Campos M; Stradella A; Lopez-Ojeda A; Ponce J; Pla MJ; Pernas S
Breast Cancer Res Treat; 2023 Jun; 199(3):445-456. PubMed ID: 37043108
[TBL] [Abstract][Full Text] [Related]
11. Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy.
McKevitt E; Cheifetz R; DeVries K; Laws A; Warburton R; Gondara L; Lohrisch C; Nichol A
Ann Surg Oncol; 2021 Oct; 28(11):5950-5957. PubMed ID: 33817760
[TBL] [Abstract][Full Text] [Related]
12. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
13. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Basik M; Florianova L; Margolese R; Dumitra S; Muanza T; Carbonneau A; Ferrario C; Boileau JF
Ann Surg Oncol; 2021 May; 28(5):2621-2629. PubMed ID: 33095362
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Damin AP; Zancan M; Melo MP; Biazus JV
Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study.
Zheng Q; Luo H; Xia W; Lu Q; Jiang K; Hong R; Xu F; Wang S
Breast Cancer Res Treat; 2022 Dec; 196(3):613-622. PubMed ID: 36207619
[TBL] [Abstract][Full Text] [Related]
16. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer.
Carleton N; Zou J; Fang Y; Koscumb SE; Shah OS; Chen F; Beriwal S; Diego EJ; Brufsky AM; Oesterreich S; Shapiro SD; Ferris R; Emens LA; Tseng G; Marroquin OC; Lee AV; McAuliffe PF
JAMA Netw Open; 2021 Apr; 4(4):e216322. PubMed ID: 33856473
[TBL] [Abstract][Full Text] [Related]
17. Use of sentinel lymph node biopsy in elderly patients with breast cancer - 10-year experience from a Swiss university hospital.
Heidinger M; Maggi N; Dutilh G; Mueller M; Eller RS; Loesch JM; Schwab FD; Kurzeder C; Weber WP
World J Surg Oncol; 2023 Jun; 21(1):176. PubMed ID: 37287038
[TBL] [Abstract][Full Text] [Related]
18. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
Malter W; Hellmich M; Badian M; Kirn V; Mallmann P; Krämer S
Anticancer Res; 2018 Jun; 38(6):3657-3662. PubMed ID: 29848724
[TBL] [Abstract][Full Text] [Related]
19. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
[TBL] [Abstract][Full Text] [Related]
20. No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial.
Jung JG; Ahn SH; Lee S; Kim EK; Ryu JM; Park S; Lim W; Jung YS; Chung IY; Jeong J; Chang JH; Shin KH; Chang JM; Moon WK; Han W
BMC Cancer; 2022 Feb; 22(1):189. PubMed ID: 35184724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
